Aims to accelerate EQRx's pipeline leveraging Evotec's data-driven, integrated R&D-platform, applied across different drug modalities and therapeutic areas.
License agreement aims to progress another poorly water soluble drug candidate into the clinic using SeraNovo's deep eutectic solvent formulation platform.
End-to-end manufacturing ensures patient-focused product design, supply chain optimization and diversified production to speed time to market and reduce risk.